Adaptive Biotechnologies President and COO Julie Rubinstein Reports Sale of $897,355.59 in Common Shares

Adaptive Biotechnologies President and COO Julie Rubinstein sold 35,643 common shares Oct. 14-16, 2026. She exercised stock options for 35,643 common shares at $12.14 per share during the same period. Her direct common stock holdings remained at 377,802 shares; remaining stock options totaled 237,205. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001780664-26-000041), on October 16, 2026, and is solely responsible for the information contained therein. (C)